This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Conference 2024 - Rare Disease Summit
March 19-21, 2024
Pre-Conference Workshops on March 18, 2024Philadelphia Marriott Downtown | Philadelphia, PA

Devin Rosenthal
Vice President, Head of Due Diligence at NovaQuest Capital Management


Dr. Rosenthal has broad operational and strategic experience across a range of therapeutic areas, stages of development, and company types within the biopharmaceutical industry. As a member of the NovaQuest Product Finance investment team, he is responsible for investment due diligence, deal sourcing, and transaction structuring.

Prior to NovaQuest, Devin was a Senior Consultant at Triangle Insights Group, a boutique life sciences strategy consulting firm, where he focused on corporate strategy, due diligence, mergers and acquisitions, and commercial forecasting. His earlier industry experience includes work in integrated product development and regulatory affairs at Rho, a mid-size contract research organization; companion diagnostics at Novartis Oncology; and clinical development at Boston Biomedical Inc, all following postdoctoral training at Tufts University’s Molecular Oncology Research Institute.

Devin holds a PhD in cellular and molecular biology from the University of Michigan, an executive MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill (finance concentration), and a BS in biology from the University of North Carolina at Wilmington.

Agenda Sessions

  • Investor Panel – Unlocking Rare Disease Investment Success through Valuation, Risk, and Innovation